Is raising HDL a futile strategy for atheroprotection? (Q37073546)

18 August 2017

1 reference

title

Is raising HDL a futile strategy for atheroprotection? (English)

1 reference

18 August 2017

2

Robert A Hegele

0 references

author name string

Tisha Joy

series ordinal

1

1 reference

18 August 2017

1 February 2008

1 reference

Nature Reviews Drug Discovery

18 August 2017

1 reference

18 August 2017

7

1 reference

18 August 2017

2

1 reference

18 August 2017

143-155

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd2489

18 August 2017

0 references

cites work

Cholesteryl ester transfer protein inhibitor (JTT-705) and the development of atherosclerosis in rabbits with severe hypercholesterolaemia

1 reference

Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression.

21 January 2018

1 reference

Viewpoint: are studies in genetically altered mice out of control?

21 January 2018

1 reference

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

21 January 2018

1 reference

Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice

21 January 2018

1 reference

A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux

21 January 2018

1 reference

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

Effect of torcetrapib on the progression of coronary atherosclerosis

31 March 2020

1 reference

Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia

31 March 2020

1 reference

Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial

31 March 2020

1 reference

High-density lipoprotein as a therapeutic target: a systematic review

31 March 2020

1 reference

Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis

31 March 2020

1 reference

Molecular regulation of HDL metabolism and function: implications for novel therapies

31 March 2020

1 reference

Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?

31 March 2020

1 reference

Differential effects of HDL subpopulations on cellular ABCA1- and SR-BI-mediated cholesterol efflux

31 March 2020

1 reference

Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease

31 March 2020

1 reference

High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study

31 March 2020

1 reference

Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial

31 March 2020

1 reference

Change in alpha1 HDL concentration predicts progression in coronary artery stenosis

31 March 2020

1 reference

Visceral Obesity in Men: Associations With Glucose Tolerance, Plasma Insulin, and Lipoprotein Levels

31 March 2020

1 reference

Inverse relationship between blood levels of high density lipoprotein subfraction 2 and magnitude of postprandial lipemia

31 March 2020

1 reference

High density and low density lipoprotein subfractions in survivors of myocardial infarction and in control subjects

31 March 2020

1 reference

Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress.

31 March 2020

1 reference

Relationship of alcohol consumption to changes in HDL-subfractions

31 March 2020

1 reference

Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein

31 March 2020

1 reference

Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity

31 March 2020

1 reference

High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion Molecules

31 March 2020

1 reference

HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3.

31 March 2020

1 reference

HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE-dependent pathway: effects on COX-2/PGI-synthase coupling.

31 March 2020

1 reference

Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets

31 March 2020

1 reference

OxLDL immune complexes activate complement and induce cytokine production by MonoMac 6 cells and human macrophages

31 March 2020

1 reference

Impact of antioxidants and HDL on glycated LDL-induced generation of fibrinolytic regulators from vascular endothelial cells

31 March 2020

1 reference

Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor

31 March 2020

1 reference

HDL and arteriosclerosis: beyond reverse cholesterol transport

31 March 2020

1 reference

High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C.

31 March 2020

1 reference

Genetic factors affecting HDL levels, structure, metabolism and function

31 March 2020

1 reference

HDL3 exerts more powerful anti-oxidative, protective effects against copper-catalyzed LDL oxidation than HDL2

31 March 2020

1 reference

2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis.

31 March 2020

1 reference

Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization

31 March 2020

1 reference

Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study

31 March 2020

1 reference

Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin

31 March 2020

1 reference

Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B

31 March 2020

1 reference

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

31 March 2020

1 reference

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

31 March 2020

1 reference

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

31 March 2020

1 reference

Expression of cholesteryl ester transfer protein in human atherosclerotic lesions and its implication in reverse cholesterol transport

31 March 2020

1 reference

Possible role for intracellular cholesteryl ester transfer protein in adipocyte lipid metabolism and storage

31 March 2020

1 reference

Deficiency of serum cholesteryl-ester transfer activity in patients with familial hyperalphalipoproteinaemia

31 March 2020

1 reference

Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation

31 March 2020

1 reference

Inhibition of CETP activity by torcetrapib reduces susceptibility to diet-induced atherosclerosis in New Zealand White rabbits

31 March 2020

1 reference

A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits

31 March 2020

1 reference

Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study

31 March 2020

1 reference

Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib

31 March 2020

1 reference

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels

31 March 2020

1 reference

Elevated HDL cholesterol is a risk factor for ischemic heart disease in white women when caused by a common mutation in the cholesteryl ester transfer protein gene

31 March 2020

1 reference

An increased coronary risk is paradoxically associated with common cholesteryl ester transfer protein gene variations that relate to higher high-density lipoprotein cholesterol: a population-based study

31 March 2020

1 reference

Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo

31 March 2020

1 reference

Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits

31 March 2020

1 reference

Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis

31 March 2020

1 reference

Important role for bone marrow-derived cholesteryl ester transfer protein in lipoprotein cholesterol redistribution and atherosclerotic lesion development in LDL receptor knockout mice.

31 March 2020

1 reference

Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene

31 March 2020

1 reference

Cholesteryl ester transfer protein (CETP) expression protects against diet induced atherosclerosis in SR-BI deficient mice.

31 March 2020

1 reference

Cholesteryl ester transfer protein corrects dysfunctional high density lipoproteins and reduces aortic atherosclerosis in lecithin cholesterol acyltransferase transgenic mice

31 March 2020

1 reference

The problem of passenger genes in transgenic mice

31 March 2020

1 reference

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels

31 March 2020

1 reference

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

31 March 2020

1 reference

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

31 March 2020

1 reference

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

31 March 2020

1 reference

The failure of torcetrapib: was it the molecule or the mechanism?

31 March 2020

1 reference

The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results

31 March 2020

1 reference

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies

31 March 2020

1 reference

HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathway

31 March 2020

1 reference

Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL.

31 March 2020

1 reference

Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion.

31 March 2020

1 reference

Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action

31 March 2020

1 reference

Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia

31 March 2020

1 reference

Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial

31 March 2020

1 reference

Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial

31 March 2020

1 reference

Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial

31 March 2020

1 reference

The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3

31 March 2020

1 reference

Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with sta

31 March 2020

1 reference

Niacin, lipids, and heart disease

31 March 2020

1 reference

PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect

31 March 2020

1 reference

Molecular identification of nicotinic acid receptor

31 March 2020

1 reference

Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1

31 March 2020

1 reference

Niacin therapy in atherosclerosis

31 March 2020

1 reference

Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice

31 March 2020

1 reference

Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol

31 March 2020

1 reference

Effects of extended-release niacin on lipoprotein subclass distribution

31 March 2020

1 reference

Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives

31 March 2020

1 reference

Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients

31 March 2020

1 reference

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

31 March 2020

1 reference

Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis

31 March 2020

1 reference

HDL therapy for the acute treatment of atherosclerosis

31 March 2020

1 reference

Oral Synthetic Phospholipid (DMPC) Raises High-Density Lipoprotein Cholesterol Levels, Improves High-Density Lipoprotein Function, and Markedly Reduces Atherosclerosis in Apolipoprotein E–Null Mice

31 March 2020

1 reference

Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles

31 March 2020

1 reference

Phosphatidylinositol promotes cholesterol transport and excretion

31 March 2020

1 reference

Phosphatidylinositol increases HDL-C levels in humans

31 March 2020

1 reference

Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits

31 March 2020

1 reference

Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits

31 March 2020

1 reference

Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein

31 March 2020

1 reference

High-density lipoprotein restores endothelial function in hypercholesterolemic men.

31 March 2020

1 reference

Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis

31 March 2020

1 reference

Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol

31 March 2020

1 reference

Effects of D-4F on vasodilation and vessel wall thickness in hypercholesterolemic LDL receptor-null and LDL receptor/apolipoprotein A-I double-knockout mice on Western diet

31 March 2020

1 reference

L-4F, an Apolipoprotein A-1 Mimetic, Dramatically Improves Vasodilation in Hypercholesterolemia and Sickle Cell Disease

31 March 2020

1 reference

Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice.

31 March 2020

1 reference

Potential clinical utility of high-density lipoprotein-mimetic peptides

31 March 2020

1 reference

A-IMilano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family

31 March 2020

1 reference

Wild-type ApoA-I and the Milano variant have similar abilities to stimulate cellular lipid mobilization and efflux

31 March 2020

1 reference

Gene transfer of wild-type apoA-I and apoA-I Milano reduce atherosclerosis to a similar extent

31 March 2020

1 reference

PPARs: therapeutic targets for metabolic disease

31 March 2020

1 reference

Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with type 2 diabetes

31 March 2020

1 reference

Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monother

31 March 2020

1 reference

Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus

31 March 2020

1 reference

Hepatic proprotein convertases modulate HDL metabolism

31 March 2020

1 reference

Endothelial lipase concentrations are increased in metabolic syndrome and associated with coronary atherosclerosis

31 March 2020

1 reference

A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism

31 March 2020

1 reference

Influence of the high density lipoprotein receptor SR-BI on reproductive and cardiovascular pathophysiology

31 March 2020

1 reference

Loss of SR-BI expression leads to the early onset of occlusive atherosclerotic coronary artery disease, spontaneous myocardial infarctions, severe cardiac dysfunction, and premature death in apolipoprotein E-deficient mice

31 March 2020

1 reference

Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia

31 March 2020

1 reference

Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles

31 March 2020

1 reference

Tissue-specific induction of intestinal ABCA1 expression with a liver X receptor agonist raises plasma HDL cholesterol levels.

31 March 2020

1 reference

Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator

31 March 2020

1 reference

Ligand activation of LXR beta reverses atherosclerosis and cellular cholesterol overload in mice lacking LXR alpha and apoE

31 March 2020

1 reference

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

31 March 2020

1 reference

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

31 March 2020

1 reference

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

31 March 2020

1 reference

Combination diet and exercise interventions for the treatment of dyslipidemia: an effective preliminary strategy to lower cholesterol levels?

31 March 2020

1 reference

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

31 March 2020

1 reference

Intensive lifestyle changes for reversal of coronary heart disease

31 March 2020

1 reference

Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?

31 March 2020

1 reference

Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein

31 March 2020

1 reference

High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressing lecithin-cholesteryl acyltransferase

31 March 2020

1 reference

Genetic cholesteryl ester transfer protein deficiency is extremely frequent in the Omagari area of Japan. Marked hyperalphalipoproteinemia caused by CETP gene mutation is not associated with longevity

31 March 2020

1 reference

Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid

31 March 2020

1 reference

Compliance problems, placebo effect cloud trials of topical analgesic

31 March 2020

1 reference

Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRD2489

1 reference

18 August 2017

1 reference

PubMed ID

18239670